David Arthur, Salarius Pharmaceuticals CEO
Salarius Pharmaceuticals sees withdrawals, 3 of 13 patient responders in sarcoma trial
The Houston-based biotech Salarius Pharmaceuticals is lifting the cover on data from a Phase I/II trial for a drug currently on voluntary hold after a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
